David Brinton

Cooley previously advised Impact Analytics, a leader in artificial intelligence (AI)-native innovation and the only provider of an end-to-end platform for pricing, merchandising and supply chain on the close of its Series D funding round led by Blue Cloud Ventures.

Cooley advised Aclaris Therapeutics (Nasdaq: ACRS), a clinical-stage biopharmaceutical company developing novel drug candidates for immuno-inflammatory diseases, on its exclusive license agreement with Biosion and $80 million private placement.

The Chapter 11 plan of PhaseBio Pharmaceuticals, a long-standing Cooley life sciences client, has gone effective following the court’s confirmation of the Chapter 11 plan on June 26, 2024. The plan provides for a global settlement with the official committee of unsecured creditors and a settlement with PhaseBio’s former co-development partner. The Chapter 11 bankruptcy case in the US Bankruptcy Court for the District of Delaware was handled by a multioffice, cross-disciplinary Cooley team.

Cooley advised Impact Analytics, a provider of the industry’s most innovative retail, grocery, consumer packaged goods, and supply chain-focused planning and merchandising software suite, on the close of its $40 million growth financing.

Cooley advised MapLight Therapeutics, a clinical-stage biopharmaceutical company, on its oversubscribed $225 million Series C financing.